Document Mentions (3 shared documents)

EFTA02295528

2 mentions1 same-page

Page ?Same page

lable USA Cleantech Fund #1 $35M ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DACART CAPITAL LLC EFTA_R1_01138806 EFTA02295532 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 M&A's, 1 IPO •

regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, D

EFTA00506107

2 mentions1 same-page

Page ?Same page

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506111 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO • >$50

EFTA00506157

2 mentions1 same-page

Page ?Same page

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506160 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO •

Mutual Connections (64)

Entities connected to both David Carter and Biolitec Pharma Ltd.

ConcentRx

PERSON

5 w/ David·2 w/ Biolitec

OvationBio

ORGANIZATION

5 w/ David·2 w/ Biolitec

Target